Mario Balsa, Medical Oncology Resident at Catalan Institute of Oncology, shared a post on X, about a recent article by M. Fassan et al. published in ESMO Gastrointestinal Oncology
“Systematic review of CLDN18.2 in advanced gastric/GEJ adenocarcinoma:
- 17 studies, mixed findings
- No consistent link to survival or clinico-path features
- Variability in assays limits conclusions
Prognosis remains…a tight junction to solve.”
Title: The prognostic role of Claudin 18.2 in advanced gastric or gastroesophageal junction adenocarcinoma: a systematic literature review
Authors: M. Fassan, I. Chau, H. Dasghaib, J. Hill, R. Pophale, K. Shitara
Read the Full Article on ESMO Gastrointestinal Oncology
More posts featuring Mario Balsa.